These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 14577653)

  • 21. A non-invasive, multi-target approach to treat diabetic retinopathy.
    Julius A; Hopper W
    Biomed Pharmacother; 2019 Jan; 109():708-715. PubMed ID: 30551523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of aldose reductase inhibition and docking studies of 6'-nitro and 6',6''-dinitrorosmarinic acids.
    Koukoulitsa C; Bailly F; Pegklidou K; Demopoulos VJ; Cotelle P
    Eur J Med Chem; 2010 Apr; 45(4):1663-6. PubMed ID: 20071057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aldose reductase inhibitors from the nature.
    Kawanishi K; Ueda H; Moriyasu M
    Curr Med Chem; 2003 Aug; 10(15):1353-74. PubMed ID: 12871134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Residues affecting the catalysis and inhibition of rat lens aldose reductase.
    Carper DA; Hohman TC; Old SE
    Biochim Biophys Acta; 1995 Jan; 1246(1):67-73. PubMed ID: 7811733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aldose reductase and its inhibition in the control of diabetic complications.
    Narayanan S
    Ann Clin Lab Sci; 1993; 23(2):148-58. PubMed ID: 8457142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aldose reductase inhibitors and diabetic kidney disease.
    Oates PJ
    Curr Opin Investig Drugs; 2010 Apr; 11(4):402-17. PubMed ID: 20336588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the effects of Zopolrestat and Sorbinil on lens myo-inositol influx.
    Beyer-Mears A; Diecke FP; Mistry K; Cruz E
    Pharmacology; 1997 Feb; 54(2):76-83. PubMed ID: 9088040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and structure-activity relationship studies of quinoxaline derivatives as aldose reductase inhibitors.
    Wu B; Yang Y; Qin X; Zhang S; Jing C; Zhu C; Ma B
    ChemMedChem; 2013 Dec; 8(12):1913-7. PubMed ID: 24115741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Edible vegetables as a source of aldose reductase differential inhibitors.
    Balestri F; Sorce C; Moschini R; Cappiello M; Misuri L; Del Corso A; Mura U
    Chem Biol Interact; 2017 Oct; 276():155-159. PubMed ID: 28159579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options.
    Srivastava SK; Ramana KV; Bhatnagar A
    Endocr Rev; 2005 May; 26(3):380-92. PubMed ID: 15814847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats.
    Cameron NE; Cotter MA; Basso M; Hohman TC
    Diabetologia; 1997 Mar; 40(3):271-81. PubMed ID: 9084964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic derangement in ischemic heart disease and its therapeutic control.
    Ferrari R; Pepi P; Ferrari F; Nesta F; Benigno M; Visioli O
    Am J Cardiol; 1998 Sep; 82(5A):2K-13K. PubMed ID: 9737480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aldose reductase catalysis and crystallography. Insights from recent advances in enzyme structure and function.
    Petrash JM; Tarle I; Wilson DK; Quiocho FA
    Diabetes; 1994 Aug; 43(8):955-9. PubMed ID: 8039602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heme oxygenase-1: an important therapeutic target for protecting against myocardial ischemia and reperfusion injury.
    Hu X; Wang J; Jiang H
    Int J Cardiol; 2013 Jul; 167(2):587-8. PubMed ID: 23084548
    [No Abstract]   [Full Text] [Related]  

  • 35. Aldose Reductase as a Drug Target for Treatment of Diabetic Nephropathy: Promises and Challenges.
    ElGamal H; Munusamy S
    Protein Pept Lett; 2017; 24(1):71-77. PubMed ID: 27894247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Requirement of aldose reductase for the hyperglycemic activation of protein kinase C and formation of diacylglycerol in vascular smooth muscle cells.
    Ramana KV; Friedrich B; Tammali R; West MB; Bhatnagar A; Srivastava SK
    Diabetes; 2005 Mar; 54(3):818-29. PubMed ID: 15734861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular modeling studies of the binding modes of aldose reductase inhibitors at the active site of human aldose reductase.
    Lee YS; Chen Z; Kador PF
    Bioorg Med Chem; 1998 Oct; 6(10):1811-9. PubMed ID: 9839011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective irreversible inhibitors of aldose reductase.
    Smar MW; Ares JJ; Nakayama T; Itabe H; Kador PF; Miller DD
    J Med Chem; 1992 Mar; 35(6):1117-20. PubMed ID: 1552504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites.
    El-Kabbani O; Wilson DK; Petrash M; Quiocho FA
    Mol Vis; 1998 Sep; 4():19. PubMed ID: 9756955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dietary sources of aldose reductase inhibitors: prospects for alleviating diabetic complications.
    Saraswat M; Muthenna P; Suryanarayana P; Petrash JM; Reddy GB
    Asia Pac J Clin Nutr; 2008; 17(4):558-65. PubMed ID: 19114390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.